Microorganisms (Basel), 2024-03, Vol.12 (3), p.596
2024
Details
- Autor(en) / Beteiligte
- Titel
- Therapy of Mycobacterium abscessus Infections in Solid Organ Transplant Patients
- Ist Teil von
- Microorganisms (Basel), 2024-03, Vol.12 (3), p.596
- Ort / Verlag
- Switzerland: MDPI AG
- Erscheinungsjahr
- 2024
- Link zum Volltext
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- complex (MABC), a rapidly growing , is one of the most common causes of non-tuberculous mycobacteria (NTM) infections in the United States of America, and it has been associated with a wide spectrum of infections in immunocompetent and immunosuppressed individuals. Eradicating MABC is very challenging, even with prolonged combination therapies. The management of MABC infections in solid organ transplant (SOT) patients is usually complex given their net state of immunosuppression, associated comorbidities, and potential drug-drug interactions, among other things. In this manuscript, we discussed the antimicrobial management of pulmonary and extrapulmonary MABC infections. In addition, we reviewed promising novel therapies such as clofazimine, omadacycline, bedaquiline, and inhaled tigecycline that could join the existing antimicrobial armamentarium to fight this infection associated with significant morbidity and mortality. However, further studies are needed, especially among the immunocompromised host.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 2076-2607eISSN: 2076-2607DOI: 10.3390/microorganisms12030596Titel-ID: cdi_doaj_primary_oai_doaj_org_article_f6b18833a356463897dada49a9b6c573
- Format
- –
- Schlagworte
- Antibiotics, Biofilms, Clofazimine, Comorbidity, Cystic fibrosis, Disease, Drug interaction, Immunosuppression, Infections, lung transplant patients, Lung transplants, management, Morbidity, Mortality, Mycobacterium abscess complex, Mycobacterium abscessus, novel therapies, Patients, Review, solid organ transplant patients, Tigecycline